Guided Therapeutics Inc (OTC: GTHP)

Guided Therapeutics Inc focuses on developing innovative medical devices aimed at improving healthcare, with a primary emphasis on the sales and marketing of its LuViva® Advanced Cervical Scan. This non-invasive cervical cancer detection device leverages biophotonics technology to identify cervical cancers and precancers painlessly and at the point of care. The company's technology scans the cervix with light, analyzing the reflected and fluorescent light to indicate the likelihood of cervical cancer or precancers. LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection, improving patient well-being by eliminating pain and providing rapid results.

Guided Therapeutics generates revenue through the sales of its LuViva device and related single-use disposable cervical guides. The company operates in the medical technology industry, catering to both developed and developing markets. In developed markets, LuViva is positioned as a triage tool following traditional screening methods, reducing the number of unnecessary follow-up tests. In developing markets, where infrastructure for traditional cancer-screening methods is limited, LuViva serves as a primary screening tool, partnering with governments or non-governmental agencies to provide immediate access to cervical cancer detection.

• LuViva Advanced Cervical Scan: This segment focuses on the sales and marketing of the LuViva device, which is designed to identify cervical cancers and precancers non-invasively. The device is marketed in both developed and developing countries, with a focus on regions where traditional screening methods are either costly or non-existent. The LuViva device is supported by single-use disposable cervical guides, which are essential for its operation. The company has executed formal distribution agreements covering over 40 countries, with active contracts in place for countries including China, Southeast Asia, Central & Eastern Europe, and Russia. The device has previously obtained regulatory approval in Europe under the Edition 3 CE Mark and has been approved for sales and marketing in India. The company is currently seeking regulatory approval to market LuViva in the United States but has not yet received approval from the U.S. Food and Drug Administration (FDA). As of December 31, 2024, the company has sold 148 LuViva devices and approximately 78,950 single-use disposable cervical guides to international distributors.

Guided Therapeutics operates in a competitive industry, facing challenges from established cervical cancer detection and prevention products such as the Pap test, HPV test, and colposcopy. Key competitors include Hologic, which offers the Thin-Prep test, and Qiagen, which provides HPV testing. Additionally, companies like Spectrascience, Dysis, and Zedco are developing technologies that could potentially compete with LuViva. However, Guided Therapeutics holds a unique position with its biophotonic technology, which has been clinically validated and published in leading peer-reviewed journals. The company's strengths include the engineering and production risks being largely addressed, regulatory approvals granted in over 40 countries, and legitimate pathways for securing marketing approvals in the two largest medical markets—the US and China—within a 1-2 year period. The clinical results of the technology have been published by world-renowned physicians, further enhancing its credibility.

The company's customer base includes international distributors and healthcare providers in both developed and developing countries. Guided Therapeutics works with country-specific or regional distributors to sell its products, focusing on markets with large screening populations and significant clinical needs. The company's distributors include Shandong Medical Instrumentation Co. Ltd. in China and Newmars Technologies, Inc. in Eastern Europe and Russia. The ongoing conflict in Ukraine may delay regulatory approval in Russia but does not affect existing contracts with the distribution partner for Eastern Europe and Russia. Guided Therapeutics remains committed to obtaining U.S. FDA approval as a priority while concentrating on international markets with large screening populations and significant clinical needs.